Morgan Stanley Upgrades Insmed to Overweight, Raises Price Target to $212

Morgan Stanley analyst Matthew Harrison has upgraded Insmed (NASDAQ: INSM) from Equal-Weight to Overweight. The price target for the stock has been raised from $166 to $212.